MRUS:NSD-Merus BV (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 47.19

Change

-0.31 (-0.65)%

Market Cap

USD 3.42B

Volume

0.26M

Analyst Target

USD 19.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

+8.81 (+0.85%)

USD 126.22B
VRTX Vertex Pharmaceuticals Inc

+1.39 (+0.30%)

USD 120.00B
ALNY Alnylam Pharmaceuticals Inc

+1.84 (+0.67%)

USD 35.01B
ARGX argenx NV ADR

-24.43 (-4.45%)

USD 32.83B
MRNA Moderna Inc

+0.29 (+0.46%)

USD 25.25B
BGNE BeiGene Ltd

+5.81 (+2.81%)

USD 22.45B
SMMT Summit Therapeutics PLC

+0.17 (+0.75%)

USD 17.92B
RPRX Royalty Pharma Plc

+0.54 (+1.95%)

USD 16.34B
UTHR United Therapeutics Corporatio..

-1.79 (-0.50%)

USD 15.71B
PCVX Vaxcyte Inc

-2.02 (-1.78%)

USD 14.50B

ETFs Containing MRUS

SBIO ALPS Medical Breakthrough.. 2.22 % 0.50 %

+0.12 (+0.31%)

USD 0.12B
GWX SPDR® S&P International .. 0.00 % 0.40 %

+0.87 (+0.31%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 71.60% 87% B+ 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 71.60% 87% B+ 93% A
Trailing 12 Months  
Capital Gain 92.85% 86% B+ 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 92.85% 86% B+ 92% A
Trailing 5 Years  
Capital Gain 158.29% 86% B+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 158.29% 86% B+ 87% B+
Average Annual (5 Year Horizon)  
Capital Gain 38.61% 82% B 87% B+
Dividend Return 38.61% 81% B- 87% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 57.79% 56% F 30% F
Risk Adjusted Return 66.81% 98% N/A 87% B+
Market Capitalization 3.42B 93% A 85% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector